Point of Care Nano-Technology, Inc. (PCNT)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -78.01 Thousand USD | -22.83% |
| 2022 | -63.51 Thousand USD | -746.87% |
| 2021 | -7500.00 USD | 41.13% |
| 2020 | -12.74 Thousand USD | 0.0% |
| 2015 | -118.8 Million USD | -62625.99% |
| 2014 | -189.39 Thousand USD | -48.25% |
| 2013 | -127.75 Thousand USD | 17.13% |
| 2012 | -154.17 Thousand USD | 73.29% |
| 2011 | -577.29 Thousand USD | -171.74% |
| 2010 | -212.44 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -78.01 Thousand USD | -22.83% |
| 2023 Q4 | -27.01 Thousand USD | -176.47% |
| 2023 Q3 | -9773.00 USD | 25.71% |
| 2023 Q2 | -13.15 Thousand USD | -34.61% |
| 2023 Q1 | -9773.00 USD | 25.71% |
| 2022 Q4 | -13.15 Thousand USD | -125.37% |
| 2022 FY | -63.51 Thousand USD | -746.87% |
| 2022 Q1 | -42.25 Thousand USD | -463.4% |
| 2022 Q2 | -13.79 Thousand USD | 67.35% |
| 2022 Q3 | -5837.00 USD | 57.69% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q4 | -7500.00 USD | 0.0% |
| 2021 FY | -7500.00 USD | 41.13% |
| 2021 Q3 | - USD | 0.0% |
| 2020 FY | -12.74 Thousand USD | 0.0% |
| 2015 Q3 | -118.28 Million USD | -247368.45% |
| 2015 Q2 | -47.79 Thousand USD | 86.06% |
| 2015 Q1 | -342.89 Thousand USD | -834.96% |
| 2015 FY | -118.8 Million USD | -62625.99% |
| 2015 Q4 | -131.69 Thousand USD | 99.89% |
| 2014 FY | -189.39 Thousand USD | -48.25% |
| 2014 Q4 | -36.67 Thousand USD | 34.14% |
| 2014 Q2 | -67.33 Thousand USD | -98.38% |
| 2014 Q1 | -33.94 Thousand USD | -25.42% |
| 2014 Q3 | -55.68 Thousand USD | 17.29% |
| 2013 Q1 | -43.03 Thousand USD | -46.63% |
| 2013 FY | -127.75 Thousand USD | 17.13% |
| 2013 Q3 | -26.65 Thousand USD | 14.05% |
| 2013 Q2 | -31.01 Thousand USD | 27.93% |
| 2013 Q4 | -27.06 Thousand USD | -1.53% |
| 2012 Q3 | -36.41 Thousand USD | 3.76% |
| 2012 Q4 | -29.34 Thousand USD | 19.41% |
| 2012 FY | -154.17 Thousand USD | 73.29% |
| 2012 Q1 | -50.57 Thousand USD | 16.85% |
| 2012 Q2 | -37.83 Thousand USD | 25.19% |
| 2011 Q1 | -439.84 Thousand USD | 0.0% |
| 2011 Q2 | -23.97 Thousand USD | 94.55% |
| 2011 Q3 | -52.64 Thousand USD | -119.59% |
| 2011 Q4 | -60.82 Thousand USD | -15.54% |
| 2011 FY | -577.29 Thousand USD | -171.74% |
| 2010 FY | -212.44 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | 89.754% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 99.096% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 99.746% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 99.937% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 99.515% |
| Better Therapeutics, Inc. | -39.76 Million USD | 99.804% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 99.586% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 99.575% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 99.782% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 99.784% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 99.932% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | 96.53% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 99.896% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 99.868% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 98.697% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 99.634% |
| Molecular Templates, Inc. | -8.12 Million USD | 99.04% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 99.486% |
| NexImmune, Inc. | -32.34 Million USD | 99.759% |
| Orgenesis Inc. | -55.36 Million USD | 99.859% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 99.691% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 99.573% |
| Scopus BioPharma Inc. | -11.6 Million USD | 99.328% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 99.986% |
| Statera Biopharma, Inc. | -174.4 Million USD | 99.955% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 97.826% |
| Trevena, Inc. | -40.28 Million USD | 99.806% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -37.031% |
| Vaccinex, Inc. | -20.25 Million USD | 99.615% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | 93.4% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 99.847% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 98.997% |